Belzupacap sarotalocan via suprachoroidal administration demonstrated positive interim phase 2 safety and efficacy data at an average of 9 months follow-up for the treatment of early-stage choroidal melanoma.
In the ongoing trial, belzupacap sarotalocan (bel-sar), also known as AU-011, is being evaluated for tumor control and visual acuity preservation after up to three cycles of treatment by single and multiple ascending doses, according to a press release from Aura Biosciences. Twenty patients have been enrolled in the trial, and in cohorts 5 and 6, there was a statistically significant